Clearline Capital LP Collegium Pharmaceutical, Inc Transaction History

Clearline Capital LP

  • $2.27 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$21.23 - $24.28 $185,847 - $212,547
8,754 Added 9.44%
101,498 $2.27 Million
Q2 2023

Aug 14, 2023
BUY
$21.06 - $24.0 $1.95 Million - $2.23 Million
92,744 New
92,744 $1.99 Million
Q2 2022

Aug 15, 2022
BUY
$14.22 - $20.88 $2.18 Million - $3.2 Million
153,094 New
153,094 $2.71 Million
Q3 2020

Nov 16, 2020
SELL
$15.78 - $20.82 $705,334 - $930,612
-44,698 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$15.49 - $23.51 $692,372 - $1.05 Million
44,698 New
44,698 $782,000

Others Institutions Holding COLL

# of Institutions
254
Shares Held
36.9M
Call Options Held
100K
Put Options Held
21.1K
View Full List

About COLLEGIUM PHARMACEUTICAL, INC

COLL Quotes by TradingView
  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.12B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Clearline Capital LP Portfolio

Follow Clearline Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearline Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Clearline Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email